Evidence map›Paper›PMID 29855762›Full record

ArticleTransgenic research2018

Unexpected mutations were expected and unrelated to CRISPR-Cas9 activity.

Lluis Montoliu, C Bruce A Whitelaw

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Transgenic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Importing genetically altered animals: ensuring quality.Mammalian genome : official journal of the International Mammalian Genome Society · 2022
    Review
  3. Review
  4. CRISPR/Cas9 engineering of albino cystinuria Type A mice.Genesis (New York, N.Y. : 2000) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lluis MontoliuNational Centre for Biotechnology (CNB-CSIC), Biomedical Research Networking Centre Consortium on Rare Diseases (CIBERER-ISCIII), Darwin 3, 28049, Madrid, Spain. montoliu@cnb.csic.es.ORCID http://orcid.org/0000-0003-3941-1176
C Bruce A WhitelawThe Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, EH25 9RG, UK. bruce.whitelaw@roslin.ed.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BBS/E/D/05251442
6 · The paper itself

Abstract

The scientific journal Nature Methods have just retracted a publication that reported numerous unexpected mutations after a CRISPR-Cas9 experiment based on collecting whole genome sequencing information from one control and two experimental genome edited mice. In the intervening 10 months since publication the data presented have been strongly contested and criticized by the scientific and biotech communities, through publications, open science channels and social networks. The criticism focused on the animal used as control, which was derived from the same mouse strain as the experimental individuals but from an unrelated sub-colony, hence control and experimental mice were genetically divergent. The most plausible explanation for the vast majority of the reported unexpected mutations were the expected underlying genetic polymorphisms that normally accumulate in two different colonies of the same mouse strain which occur as a result of spontaneous mutations and genetic drift. Therefore, the reported mutations were most likely not related to CRISPR-Cas9 activity.

Indexed as

Polymorphism, GeneticAnimalsCRISPR-Cas SystemsMiceMutagenesisMutationCas9CRISPRGene therapyGenome editing applicationsOff target mutationsSafety

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.